Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0FRWPD
ADC Name	huAb18v10-CZ
Synonyms	huAb18v10 CZ; huAb18v10CZ Click to Show/Hide
Organization	AbbVie, Inc.
Drug Status	Investigative
Indication	In total 1 Indication(s) Breast ductal carcinoma [ICD11:2C61] Investigative
Drug-to-Antibody Ratio	2.7
	3D MOL	2D MOL
Antibody Name	huAb18v10		Antibody Info
Antigen Name	CD276 antigen (CD276)		Antigen Info
Payload Name	Undisclosed
Linker Name	huAb18v10-CZ linker
Combination Type	AbbVie's CZ

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	0.57	nM	HCC38 cells	Breast ductal carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.57	nM	HCC38 cells	Breast ductal carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.57 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized chAb18 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.57 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the HCC38 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

References

Ref 1	Anti-b7-h3 antibodies and antibody drug conjugates; 2018-03-08.